Summary
The molecular mechanisms leading to androgen-independent growth in prostate cancer (PC) are poorly understood. Androgen deprivation therapy (ADT) results physiologically in a decrease in proliferation and an increase in programmed cell death (PCD)/apoptosis. The aim of our study was to get more insight into these processes in prostatic carcinomas before and after ADT. For this purpose, immunohistologic staining for the androgen receptor (AR) molecule, the Ki-67 antigen, the bcl-2 oncoprotein, the p53 protein and its physiologic effector, p21/WAF1, was performed on archival material. PCD was visualized by enzymatic detection of DNA fragmentation. Specimens from 69 PC patients after ADT were studied in correlation to histopathology and prognosis. In 42 cases, corresponding tumour tissue from the untreated primary tumours could be analysed comparatively. Before ADT, histologic grade was associated with Ki-67 index (P < 0.0001, Spearman correlation) and PCD rate (P < 0.05, Spearman correlation). Ki-67 index correlated with PCD rate (P < 0.05, Spearman correlation) and p21/WAF1 expression (P < 0.01, Fisher’s exact test). p21/WAF1 expression was the only statistically significant prognostic factor for shorter survival (P < 0.002, log-rank test). All p21/WAF1-positive cases showed high Ki-67 index and high histologic grade. After ADT, loss of AR expression was associated with high Ki-67 index, whereas histologic signs of regression correlated negatively with Ki-67 index (P < 0.001, Pearson χ2 test). p21/WAF1 expression increased significantly (P < 0.02, McNemar test) and correlated with p53 accumulation (P < 0.0001, Pearson χ2 test). Most significant prognostic parameter after conventional ADT was high-rate p21/WAF1 expression (> 50% of tumour cells; P < 0.00001, log-rank test). This study demonstrates that p21/WAF1 overexpression before and after ADT characterizes a subgroup of advanced PC with paradoxically high proliferation rate and significantly worse clinical outcome. This finding might be clinically useful for planning therapy in these patients.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ansari, B., Coates, P. J., Greenstein, B. D. & Hall, P. A. (1993). In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170: 1–8.
Blagosklonny, M. V., Prabhu, N. S. & El-Deiry, W. S. (1997). Defects in p21/WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res 57: 320–325.
Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. & Allred, D. C. (1993). p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369–3373.
Breslow, N. E. & Day, N. E. (1980). The Analysis of Case Control Studies. IARC Scientific Publications, no. 32. IARC: Lyon
Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C. & Mihatsch, M. J. (1996). Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 148: 1557–1565.
Chen, X., Bargonetti, J. & Prives, C. (1995). p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 55: 4257–4263.
Civantos, F., Marcial, M. A., Banks, E. R., Ho, C. K., Speights, V. O., Drew, P. A., Murphy, W. M. & Soloway, M. S. (1995). Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 75: 1634–1641.
Colombel, M., Symmons, F., Gil, S., O’Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S. & Buttyan, R. (1993). Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390–400.
Eastham, J. A., Stapleton, A. M. F., Gousse, A. E., Timme, T. L., Yang, G., Slawin, K. M., Wheeler, T. M., Scardino, P. T. & Thompson, T. C. (1995). Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1: 1111–1118.
El-Deiry, W. S., Harper, J. W., O’Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. & Vogelstein, B. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174.
Ellis, P. A., Lonning, P. E., Borresen-Dale, A., Aas, T., Geisler, S., Akslen, L. A., Salter, I., Smith, I. E. & Dowsett, M. (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer 76: 480–485.
Erber, R., Klein, W., Andl, T., Enders, C., Born, A. I., Conradt, C., Bartek, J. & Bosch, F. X. (1998). Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 74: 383–389.
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H. & Brooks, M. (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119–128.
Gao, X., Chen, Y. Q., Wu, N., Grignon, D. J., Sakr, W., Porter, A. T. & Honn, K. V. (1995). Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11: 1395–1398.
Gavrieli, Y., Sherman, Y. & Ben-Sasson, S. A. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493–501.
Gleason, D. F. (1992). Histologic grading of prostate cancer: a perspective. Hum Pathol 23: 273–279.
Gleason, D. F. (1966). Classification of prostatic carcinomas. Cancer Chemother Rep 50: 125–128.
Gleason, D. F. & Mellinger, G. I. (1974). Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 111: 58–64.
Gomyo, Y., Ikeda, M., Osaki, M., Tatebe, S., Tsujitani, S., Ikeguchi, M., Kaibara, N. & Ito, H. (1997). Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79: 2067–2072.
Harada, N., Gansauge, S., Gansauge, F., Gause, H., Shimoyama, S., Imaizumi, T., Mattfeld, T., Schoenberg, M. H. & Beger, H. G. (1997). Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) in pancreatic cancer. Br J Cancer 76: 299–305.
Hollander, M. & Wolfe, D. A. (1973). Non-parametric Statistical Methods. Wiley and Sons: New York.
Hölzel, D., Klamert, A. & Schmidt, M. (1996). Krebs: Häufigkeiten, Befunde und Behandlungsergebnisse. Perspektiven für die Krebsdiskussion und eine quantitative klinisch-epidemiologische Onkologie aus dem Tumorregister München. W Zucker Schwerdt Verlag: Munich
Huggins, C. & Hodges, C. V. (1941). Studies on prostatic cancer I. Cancer Res 1: 293–297.
Isaacs, J. T., Furuya, Y. & Berges, R. (1994). The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5: 391–400.
Klocker, H., Culig, Z., Hobisch, A., Cato, A. C. & Bartsch, G. (1994). Androgen receptor alterations in prostatic carcinoma. Prostate 25: 266–273.
Korsmeyer, S. J. (1992a). bcl-2: a repressor of lymphocyte death. Immunol Today 13: 285–287.
Korsmeyer, S. J. (1992b). bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879–886.
Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S. & Reed, J. C. (1996). Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567–1576.
Kubota, Y., Shuin, T., Uemura, H., Fujinami, K., Miyamoto, H., Torigoe, S., Dobashi, Y., Kitamura, H., Iwasaki, Y. & Danenberg, K. (1995). Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27: 18–24.
Lane, D. P. (1992). p53, guardian of the genome. Nature 358: 15–16.
Levine, A. J., Momand, J. & Finlay, C. A. (1991). The p53 tumour suppressor gene. Nature 351: 453
Li, Y., Jenkins, C. W., Nichols, M. A. & Xiong, Y. (1994). Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9: 2261–2268.
Lukas, J., Groshen, S., Saffari, B., Niu, N., Reles, A., Wen, W. H., Felix, J., Jones, L. A., Hall, F. L. & Press, M. F. (1997). WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 150: 167–175.
Maelandsmo, G. M., Holm, R., Fodstad, O., Kerbel, R. S. & Florenes, V. A. (1997). Cyclin kinase inhibitor p21/WAF1/CIP1 in malignant melanoma. Reduced expression in metastatic lesions. Am J Pathol 149: 1813–1822.
McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J-R, Tu, S-M & Campbell, M. L. (1992). Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940–6944.
Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E. & Givol, D. (1994). Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391–3395.
Miyamoto, K. K., McSherry, S. A., Dent, G. A., Sar, M., Wilson, E. M., French, F. S., Sharief, Y. & Mohler, J. L. (1993). Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 149: 1015–1019.
Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C. & Conti, C. J. (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657–1669.
Peterziel, H., Culig, Z., Stober, J., Hobisch, A., Radmayr, C., Bartsch, G., Klocker, H. & Cato, A. C. (1995). Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 63: 544–550.
Piffko, J., Bankfalvi, A., Öfner, D., Joos, U., Böcker, W. & Schmid, K. W. (1995). Immunohistochemical detection of p53 protein in archival tissues from squamous cell carcinomas of the oral cavity using wet autoclave antigen retrieval. J Pathol 176: 69–75.
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W. & Vogelstein, B. (1997). A model for p53-induced apoptosis. Nature 389: 300–305.
Shurbaji, M. S., Kalbfleisch, J. H. & Thurmond, T. S. (1995). Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 26: 106–109.
Stewart, B. W. (1994). Mechanisms of apoptosis: Intergration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 86: 1286–1296.
Suzuki, H., Akakura, K., Komiya, A., Aida, S., Akimoto, S. & Shimazaki, J. (1996). Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29: 153–158.
Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N. & Balk, S. P. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393–1398.
Trapman, J. & Brinkmann, A. O. (1996). The androgen receptor in prostate cancer. Pathol Res Pract 192: 752–760.
Trotter, M. J., Tang, L. & Tron, V. A. (1997). Overexpression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol 24: 265–271.
Visakorpi, T., Kallioniemi, O. P., Heikkinen, A., Koivula, T. & Isola, J. (1992). Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883–887.
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J. & Kallioniemi, O. P. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401–406.
Wang, A., Yoshimi, N., Tanaka, T. & Mori, H. (1997). WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol 123: 118–123.
Wertz, I. E., Deitch, A. D., Gumerlock, P. H., Gandour Edwards, R., Chi, S. G. & de Vere White, R. W. (1996). Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 27: 573–580.
Westin, P., Stattin, P., Damber, J. E. & Bergh, A. (1995). Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146: 1368–1375.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Baretton, G., Klenk, U., Diebold, J. et al. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80, 546–555 (1999). https://doi.org/10.1038/sj.bjc.6690390
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690390
Keywords
This article is cited by
-
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
-
Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma
Journal of Cell Communication and Signaling (2019)
-
Targeting histone deacetylase and NFκB signaling as a novel therapy for Mucoepidermoid Carcinomas
Scientific Reports (2018)
-
EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma
Scientific Reports (2016)
-
CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells
Oncogene (2015)